Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Biogen insider Priya Singhal has filed a notice to sell company stock. The filing covers a proposed sale of 2,660 shares of Biogen common stock through Fidelity Brokerage Services LLC on 02/09/2026, listed on NASDAQ, with an aggregate market value of 531,547.80.
The shares to be sold come from recent restricted stock vesting awards. She acquired 1,963 shares on 02/06/2026 and 697 shares on 02/07/2026, both described as compensation from the issuer. In the past three months, she also sold 748 common shares on 02/02/2026 for gross proceeds of 134,116.40.
Biogen Inc. describes its 2025 business, strategy and major pipeline moves in neurology, specialized immunology and rare diseases. The company markets MS drugs such as VUMERITY and TYSABRI, SPINRAZA for SMA, SKYCLARYS for Friedreich ataxia, QALSODY for SOD1 ALS, LEQEMBI for early Alzheimer’s disease and ZURZUVAE for postpartum depression, alongside multiple biosimilars and anti‑CD20 revenue-sharing products with Genentech.
Key 2025 actions include acquiring Alcyone Therapeutics for about $85 million to control ThecaFlex DRx delivery technology, entering new collaborations with Dayra, Vanqua, City Therapeutics and Stoke with upfront payments ranging from $16 million to $165 million, and securing up to $250 million in litifilimab co-funding via a $200 million Royalty Pharma development financing recorded as an R&D offset. Biogen also issued $1.75 billion of 2025 senior notes, signed a 15.5‑year lease for a 580,000‑square‑foot Cambridge headquarters to support a planned 40% Massachusetts footprint reduction, advanced multiple Phase 3 programs (including felzartamab, salanersen and zorevunersen) and recorded numerous global label and access expansions for LEQEMBI, SPINRAZA, SKYCLARYS and QALSODY.
Biogen Inc. reported mixed fourth quarter and full year 2025 results and issued 2026 guidance. Full year 2025 total revenue was $9.9 billion, up 2% from 2024, with GAAP diluted EPS of $8.79 and Non-GAAP diluted EPS of $15.28, above the prior guidance range of $14.50–$15.00. Q4 2025 revenue was $2.28 billion, down 7% year over year, with a GAAP diluted loss per share of $(0.33) and Non-GAAP diluted EPS of $1.99.
Growth products were a key driver: 2025 revenue from these medicines rose 19% year over year, offsetting declines in multiple sclerosis products (excluding VUMERITY). LEQEMBI generated about $134 million of Q4 global in‑market sales, up 54% year over year, while SKYCLARYS and ZURZUVAE also showed strong demand. Multiple sclerosis product revenue fell 7% for the year, rare disease revenue grew 8%, and biosimilars revenue declined 8%.
For 2026, Biogen expects Non-GAAP diluted EPS between $15.25 and $16.25 and total revenue to decline by a mid‑single‑digit percentage versus 2025, with gross margin and combined Non‑GAAP R&D and SG&A expenses roughly consistent year over year. The company highlighted late‑stage pipeline momentum, including FDA Priority Review for LEQEMBI IQLIK initiation and Breakthrough Therapy Designation for litifilimab in cutaneous lupus, with multiple Phase 3 readouts anticipated through 2029.
FMR LLC and Abigail P. Johnson report significant ownership of Biogen Inc.12/31/2025, they beneficially owned 9,413,062.03 shares, representing 6.4% of the class.
FMR LLC held sole voting power over 8,291,794.64 shares and sole dispositive power over 9,413,062.03 shares
Biogen Inc.’s Head of Development, Priya Singhal, reported equity transactions involving company stock. On January 30, 2026, 1,829 shares of common stock were acquired at $0 following the vesting and exercise of a restricted stock unit award granted on February 1, 2023 that vests in three equal annual installments.
Also on January 30, 2026, 582 shares were surrendered at $179.89, and on February 2, 2026, 748 shares were sold at $179.3. After these transactions, Singhal directly held 6,271.1428 shares of Biogen common stock.
A holder of 748 shares of common stock of a NASDAQ-listed company has filed a notice of proposed sale under Rule 144. The shares have an aggregate market value of 134116.40 and are planned to be sold on 02/02/2026 through Fidelity Brokerage Services LLC on NASDAQ.
The securities were recently acquired on 02/01/2026 via restricted stock vesting from the issuer as compensation. The filer represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Biogen Inc. is signaling a sizeable one-time expense in its upcoming fourth-quarter 2025 results. The company expects to record approximately $222 million of acquired in-process research and development, upfront and milestone expense on a pre-tax basis, which it estimates will reduce GAAP and non-GAAP net income per diluted share for the quarter by about $1.26.
This line item reflects costs tied to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions. Biogen began presenting this expense as a separate line item in its income statement in the first quarter of 2025 and notes that it does not forecast such costs because their timing and size are inherently uncertain. The company also emphasizes that its results for the quarter ended December 31, 2025 are preliminary and may change as normal closing procedures are completed.
Biogen Inc. President and CEO Christopher A. Viehbacher reported equity transactions in the company’s common stock. On December 1, 2025, 7,040 shares of common stock were acquired at a price of $0 per share through the exercise of previously granted restricted stock units, coded as transaction type M. On the same date, 3,404 shares of common stock were disposed of in a transaction coded F at a price of $177.78 per share. After these transactions, Viehbacher beneficially owned 16,443 shares of Biogen common stock directly. The underlying restricted stock unit award, originally granted on December 1, 2022, vested on its third anniversary and represented one share of common stock for each unit.
Biogen Inc. (BIIB) reported insider equity activity by its Head of Research. On 10/31/2025, 695 shares of common stock were acquired at $0 under a transaction coded M, reflecting settlement of previously granted RSUs. A separate transaction coded F covered 337 shares at $154.27. Following these transactions, the officer directly owned 1,791 shares of common stock.
The derivative table shows 695 restricted stock units outstanding after the activity, tied to an award granted on 11/01/2023 that vests in three equal annual installments beginning on 11/01/2024, with an expiration date of 11/01/2026.
Biogen Inc. reported Q3 2025 results in its 10-Q. Total revenue was $2,534.7 million, led by product revenue of $1,846.9 million, anti‑CD20 therapeutic programs of $493.9 million, Alzheimer’s collaboration revenue of $42.7 million, and contract manufacturing, royalty and other revenue of $151.2 million.
Operating lines showed cost of sales of $674.4 million, R&D of $436.1 million, and SG&A of $594.8 million. Net income was $466.5 million, with diluted EPS of $3.17. Comprehensive income reached $489.8 million.
On the balance sheet, cash and cash equivalents were $3,862.8 million, total assets $29,207.5 million, and notes payable $6,285.1 million. Year‑to‑date, operating cash flow was $1,692.7 million, investing cash flow $(139.4) million, and financing cash flow $(164.9) million. Shares outstanding were 146,702,272 as of October 28, 2025.